B3 S.A. Got An Antitrust Warning Because Of The Strength Of Its Moat (Rating Downgrade)

B3 S.A. reported 2Q26 revenue growth of +12% YoY and recurring EBITDA up +13% YoY, though sequential trends saw normalization alongside higher one-time expenses. For BOLSY, dominant-market status is facing heightened scrutiny as new derivatives competitors and antitrust-driven infrastructure changes threaten long-term margin durability. Despite these risks, the article argues the business moat, high margins, and capital efficiency support a 15x valuation on normalized earnings.

Analysis

For a high-margin exchange/infrastructure name, the market usually underestimates how quickly regulatory remedies can turn a “sticky” franchise into a price-competitive utility. The near-term print still matters, but the real variable is whether mandated interoperability and new derivative venues force BOLSY to spend more on tech while accepting lower take-rates; in that setup, each incremental share loss can hit EBITDA disproportionately because fixed costs are already leveraged.

The second-order winner is not necessarily another exchange, but the brokerage and trading stack around it: lower execution friction and more product choice should lift activity for firms that monetize flow, not tolls. In Brazil, that is more likely to support brokers/asset distributors than to help the incumbent market operator, especially if traders can route around the incumbent in the most fee-sensitive products. The immediate earnings reaction can stay constructive for weeks, but the 6-18 month risk is a multiple cap as the market prices BOLSY more like a regulated platform than a protected monopoly.

The contrarian view is that the market may be overfitting the antitrust headline: liquidity, clearing trust, and embedded workflows are real moat defenses, and challenger venues often need years and subsidies to matter. The thesis is falsified if competitor volumes fail to inflect after two reporting cycles or if margin guidance stays stable despite infrastructure changes. Conversely, if derivatives share loss appears before the next annual budget cycle, the rerating risk is real and fast.

Key Decisions for Investors

• Stay tactically neutral-to-slightly long BOLSY into the next print, but only add on a selloff of 5%+; the setup is more of a long-duration moat test than a clean earnings momentum trade.
• If antitrust implementation milestones advance, initiate a 3-6 month pair: long XP / short BOLSY, targeting a 1.5x-2.0x payoff if fee compression hits the exchange faster than broker activity benefits flow-through.
• For funds that need convex downside protection, buy a 6-9 month BOLSY put spread on any rally back to a full valuation regime; this is a multiple-compression hedge, not an earnings-collapse bet.
• Set a watch item on derivatives market share and EBITDA margin: a sustained >150 bps margin compression or two consecutive quarters of share loss should trigger de-risking.
• No direct trade in TGT from this setup; it has no clear second-order linkage here.